Skip to main content

Table 2 AT9 thromboembolic risk for each of the VKA indication groups

From: Guideline compliance for bridging anticoagulation use in vitamin-K antagonist patients; practice variation and factors associated with non-compliance

  Indication group: n (column %) a
AT9 Thromboembolic risk Atrial fibrillation Mechanical heart valve Venous thromboembolism
Low 131 (69) 1 (5) 6 (18)
Moderate 19 (10) 4 (20) 22 (65)
High 35 (18) 9 (45) 4 (12)
Unknown b 5 (3) 6 (30) 2 (6)
  1. AT9: Antithrombotic Therapy and Prevention of Thrombosis, Ninth Edition guideline; VKA: vitamin-K antagonist
  2. a Multiple indications are possible
  3. b Insufficient documentation of risk factors in the records, so the AT9 risk could not be determined